Rucha Patil: Our ”Factor VIII Inhibitor Point-of-Care Diagnostic” Is Successfully Transferred at Science-Tech
Rucha Patil, Scientist at Department of Haemostasis and Thrombosis, ICMR- National Institute of Immunohaematology, reposted from ICMR-NIRBID on LinkedIn:
”Reposting with immense pride and gratitude
Truly delighted to see our ‘Factor VIII Inhibitor Point-of-Care Diagnostic’ successfully transferred at Science–Tech’ on National Technology Day 2026.
Grateful to my wonderful team – Sharda Shanbhag, Sweta Kaskar, and Moni Singh – and honoured that this milestone was achieved in the presence of Hon’ble Minister Dr Jitendra Singh .
Proud to see this innovation licensed to Meril Pvt Ltd – bringing us a step closer to accessible and affordable hemophilia diagnostics.”
Quoting ICMR-National Institute for Research on Blood and Immune Disorders, (ICMR-NIRBID)‘s post:
”ICMR–NIRBID is especially proud to highlight the successful technology transfer of its novel ‘Factor VIII Inhibitor Point-of-Care Diagnostic’, developed by Rucha Patil, Sharda Shanbhag, Sweta Kaskar, and Moni Singh, at the national programme Science–Tech’ held on the occasion of National Technology Day 2026 at BRIC–National Institute of Immunology, in the presence of Jitendra Singh, Hon’ble Minister of State (Independent Charge), Ministry of Science and Technology and Ministry of Earth Sciences; MoS, PMO; Ministry of Personnel, Public Grievances and Pensions; Department of Atomic Energy; and Department of Space, Government of India.
This innovation has been licensed to Meril Life Sciences, marking a significant advancement toward enhancing accessible and timely diagnostics for hemophilia care.
The novel FVIII inhibitor POCT is a low-cost, point-of-care lateral flow assay based on gold nanoparticle technology, enabling rapid detection of FVIII inhibitors at approximately one-twentieth the cost of the gold-standard assay, while remaining unaffected by non-factor therapies.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?